结直肠癌KRAS基因突变位点与临床特征的关系
马怡晨 , 赵九洲 , 付强 , 马东阳 , 艾克热木· , 刘晓莉
中南大学学报(医学版) ›› 2026, Vol. 51 ›› Issue (5) : 947 -953.
结直肠癌KRAS基因突变位点与临床特征的关系
Relationship between KRAS gene mutation sites and clinical characteristics in colorectal cancer
,
,
目的 结直肠癌是全球高发消化道恶性肿瘤,KRAS基因突变是其重要的分子特征,但不同突变位点的临床意义差异尚未明确。本研究探讨KRAS基因特定突变位点的分布特征,分析其与结直肠癌患者临床病理参数、生存预后的关联,为精准分层诊疗提供依据。 方法 回顾性纳入2018年5月至2020年1月于郑州大学附属肿瘤医院接受手术治疗的550例结直肠癌患者,均留存肿瘤组织标本。采用聚合酶链反应(polymerase chain reaction,PCR)对所有标本进行KRAS基因突变筛查,计算总体突变率;采用Illumina Nova测序平台对其中的210例标本行高通量测序,明确KRAS基因第2号外显子第12、13位密码子的具体突变类型。收集患者年龄、性别、肿瘤分期、淋巴结转移状态、原发灶直径等临床病理资料,并通过门诊复查、电话随访获取生存数据,随访截止时间为2023年12月29日。采用单因素及多因素Cox比例风险回归模型,筛选影响患者预后的独立危险因素,变量纳入标准为单因素分析P<0.10及临床公认的关键变量(如肿瘤分期、淋巴结转移)。 结果 550例标本中,232例检出KRAS基因突变,总体突变率为42.18%。210例行高通量测序的标本中,155例检出突变,突变率为73.81%;共检出7种突变类型,其中G12D为最常见位点(19.52%),其次为G12V(12.86%)、G13D(12.86%)、G12S(10.95%)、G12A(8.57%)、G12C(8.10%)、双突变(G12D+G12V、G12V+G13D,各占0.48%)。临床特征关联分析显示:G12D突变型患者初诊时淋巴结转移比例为73.17%(30/41),显著高于野生型的38.18%(21/55;P<0.05),而原发灶直径≥4 cm的比例(36.59%)与野生型(25.45%)比较,差异无统计学意义(P>0.05);G12A、G12C、G12S、G13D突变型患者原发灶直径≥4 cm的比例分别为66.67%、76.47%、78.26%、66.67%,均显著高于野生型(均P<0.05),但淋巴结转移比例与野生型差异无统计学意义(P>0.05)。Cox比例风险回归分析结果显示:肿瘤分期Ⅲ~Ⅳ期(HR=1.820,95% CI 1.194~2.774,P=0.005)、G12C突变(HR=2.014,95% CI 1.321~3.069,P=0.001)、G12D突变(HR=1.857,95% CI 1.218~2.930,P=0.004)、G12V突变(HR=1.751,95% CI 1.149~2.669,P=0.009)是结直肠癌患者死亡的独立危险因素。 结论 KRAS基因不同突变位点与结直肠癌临床特征存在特异性关联:G12D突变与淋巴结高转移风险相关,G12A、G12C、G12S、G13D突变与原发灶体积增大相关。G12C、G12D、G12V突变是患者预后的独立危险因素,可作为风险分层与个体化治疗的潜在分子标志物。
Objective Colorectal cancer is a common gastrointestinal malignancy worldwide. KRAS gene mutation is an important molecular feature of colorectal cancer, but the clinical significance of different mutation sites remains unclear. This study aims to investigate the distribution characteristics of specific KRAS gene mutation sites and analyze their associations with clinicopathological parameters and survival outcomes in patients with colorectal cancer, thereby providing a basis for precise stratified diagnosis and treatment. Methods A total of 550 patients with colorectal cancer who underwent surgical treatment at the Affiliated Cancer Hospital of Zhengzhou University from May 2018 to January 2020 were retrospectively included, and tumor tissue specimens were retained from all patients. Polymerase chain reaction (PCR) was first used to screen all specimens for KRAS gene mutations, and the overall mutation rate was calculated. High-throughput sequencing was then performed on 210 of these specimens using the Illumina Nova sequencing platform to determine the specific mutation types at codons 12 and 13 of exon 2 of the KRAS gene. Clinicopathological data, including age, sex, tumor stage, lymph node metastasis status, and primary lesion diameter, were collected. Survival data were obtained through outpatient follow-up and telephone follow-up, with the follow-up cutoff date of December 29, 2023. Univariate and multivariate Cox proportional hazards regression models were used to identify independent risk factors affecting prognosis. Variables were included based on a univariate analysis threshold of P<0.10 and clinically recognized key variables, such as tumor stage and lymph node metastasis. Results Among the 550 specimens, KRAS gene mutations were detected in 232 cases, with an overall mutation rate of 42.18%. Among the 210 specimens subjected to high-throughput sequencing, mutations were detected in 155 cases, with a mutation rate of 73.81%. Seven mutation types were identified. G12D was the most common mutation site (19.52%), followed by G12V (12.86%), G13D (12.86%), G12S (10.95%), G12A (8.57%), G12C (8.10%), and double mutations, including G12D+G12V and G12V+G13D, each accounting for 0.48%. Analysis of associations with clinical features showed that the proportion of patients with lymph node metastasis at initial diagnosis was 73.17% (30/41) among patients with the G12D mutation, which was significantly higher than that in patients with wild-type KRAS [38.18% (21/55), P<0.05]. However, the proportion of patients with a primary lesion diameter ≥4 cm was 36.59% in the G12D mutation group, which did not differ significantly from that in the wild-type group (25.45%, P>0.05). The proportions of patients with a primary lesion diameter ≥4 cm were 66.67%, 76.47%, 78.26%, and 66.67% among patients with G12A, G12C, G12S, and G13D mutations, respectively, all of which were significantly higher than that in the wild-type group (all P<0.05). However, the proportions of lymph node metastasis in these mutation groups did not differ significantly from that in the wild-type group (P>0.05). Cox proportional hazards regression analysis demonstrated that tumor stage Ⅲ-Ⅳ (HR=1.820, 95% CI 1.194 to 2.774, P=0.005), G12C mutation (HR=2.014, 95% CI 1.321 to 3.069, P=0.001), G12D mutation (HR=1.857, 95% CI 1.218 to 2.930, P=0.004), and G12V mutation (HR=1.751, 95% CI 1.149 to 2.669, P=0.009) were independent risk factors for death in patients with colorectal cancer. Conclusion Different KRAS gene mutation sites are specifically associated with clinical features of colorectal cancer. The G12D mutation is associated with a high risk of lymph node metastasis, whereas G12A, G12C, G12S, and G13D mutations are associated with increased primary tumor size. G12C, G12D, and G12V mutations are independent prognostic risk factors and may serve as potential molecular markers for risk stratification and individualized treatment.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
林佳宁, 闫志航, 贺龙宇, |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
中国医师协会外科医师分会, 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠外科学组, |
| [9] |
Chinese College of Surgeons, Chinese Medical Doctor Association; Group of Gastrointestinal Surgery, Society of Surgery, Chinese Medical Association; Group of Colorectal Surgery, Society of Surgery, Chinese Medical Association; |
| [10] |
|
| [11] |
陆依儿, 翁姗姗, 袁瑛. 2023年ASCO转移性结直肠癌免疫治疗和靶向治疗进展[J]. 实用肿瘤杂志, 2023, 38(4): 312-317. |
| [12] |
|
| [13] |
陈香梅, 刘太锋. 靶向治疗联合化疗对转移性结直肠癌患者的效果及肿瘤标志物、Th1/Th2细胞因子的影响[J]. 河北医药, 2023, 45(15): 2305-2309. |
| [14] |
|
| [15] |
李瑞华, 韩正全. 结直肠癌的免疫及靶向治疗研究进展[J]. 齐齐哈尔医学院学报, 2023, 44(10): 979-983. |
| [16] |
|
| [17] |
陈素华, 刘朵平, 李陶威, |
| [18] |
|
| [19] |
|
| [20] |
林丽波, 陈小丽, 许可, |
| [21] |
|
| [22] |
靳杨, 姜利琼, 房烨, |
| [23] |
|
| [24] |
张琳, 陈祥义, 杨宏杰, |
| [25] |
|
| [26] |
郭慧娴, 周慧玲, 朱晓蔚, |
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
/
| 〈 |
|
〉 |